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OBJECTIVES The primary purpose of this study was to determine the acute and long-term hemodynamic
and clinical effects of irbesartan in patients with heart failure.
BACKGROUND Inhibition of angiotensin II production by angiotensin-converting enzyme (ACE) inhibitors
reduces morbidity and mortality in patients with heart failure. Irbesartan is an orally active
antagonist of the angiotensin II AT1 receptor subtype with potential efficacy in heart failure.
METHODS Two hundred eighteen patients with symptomatic heart failure (New York Heart Association
[NYHA] class II–IV) and left ventricular ejection fraction #40% participated in the study.
Serial hemodynamic measurements were made over 24 h following randomization to
irbesartan 12.5 mg, 37.5 mg, 75 mg, 150 mg or placebo. After the first dose of study
medication, patients receiving placebo were reallocated to one of the four irbesartan doses,
treatment was continued for 12 weeks and hemodynamic measurements were repeated.
RESULTS Irbesartan induced significant dose-related decreases in pulmonary capillary wedge pressure
(average change 25.9 6 0.9 mm Hg and 25.3 6 0.9 mm Hg for irbesartan 75 mg and
150 mg, respectively) after 12 weeks of therapy without causing reflex tachycardia and without
increasing plasma norepinephrine. The neurohormonal effects of irbesartan were highly
variable and none of the changes was statistically significant. There was a significant
dose-related decrease in the percentage of patients discontinuing study medication because of
worsening heart failure. Irbesartan was well tolerated without evidence of dose-related cough
or azotemia.
CONCLUSIONS Irbesartan, at once-daily doses of 75 mg and 150 mg, induced sustained hemodynamic
improvement and prevented worsening heart failure. (J Am Coll Cardiol 1999;33:1174–81)
© 1999 by the American College of Cardiology
Activation of the renin-angiotensin system in patients with
heart failure causes vasoconstriction and retention of sodium
and water (1). There is experimental and clinical evidence
that these effects are mediated in part by the stimulation of
AT1 receptors by angiotensin II (1–3). Angiotensin-
converting enzyme (ACE) inhibitors substantially improve
hemodynamic parameters, clinical status and survival of
patients with heart failure (4,5). Inhibition of angiotensin II
production by ACE inhibitors is presumed to contribute to
these beneficial effects. Despite the known benefits of ACE
inhibitors and, more recently, beta-adrenergic blocking
agents (6,7), morbidity and mortality remain unacceptably
high in patients treated with ACE inhibitors.
Indeed, the hemodynamic and clinical benefits of ACE
inhibitors may be limited by the production of angiotensin
II by enzymatic pathways that are resistant to ACE inhibi-
tion (1). In patients undergoing cardiac transplantation for
heart failure, a substantial proportion of myocardial ACE
activity remains during treatment with conventional doses
of ACE inhibitors (8). Furthermore, conversion of angio-
tensin I to angiotensin II in human myocardial tissue is
largely mediated by enzymes that are resistant to ACE
inhibition (8). These observations indicate that direct block-
ade of the AT1 receptor may have advantages over inhibi-
tion of ACE in the management of chronic heart failure.
While the potentiation of bradykinin activity by ACE
inhibitors may beneficially augment vasodilation, it is also
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likely to be responsible for some limiting side effects, such as
cough and angioedema (9,10). Accordingly, AT1 receptor
antagonists represent an alternative therapy that may pro-
vide more complete blockade of an activated renin-
angiotensin system while avoiding some of the detrimental
side effects of ACE inhibitors (11).
Irbesartan is a new, highly selective nonpeptide antago-
nist of AT1 receptors with pharmacokinetic properties that
favor once-per-day dosing (12–14). The primary objective
of this study was to determine whether irbesartan would
provide dose-related, sustained reduction in pulmonary
capillary wedge pressure (PCWP) in patients with symp-
tomatic heart failure and left ventricular systolic dysfunc-
tion. Secondary objectives included assessment of acute and
long-term hemodynamic effects, safety and clinical effects of
irbesartan in patients with heart failure.
METHODS
Study population. Patients were $18 years old, had symp-
tomatic heart failure (New York Heart Association
[NYHA] functional class II, III or IV) that required
treatment with diuretics and had left ventricular ejection
fraction (LVEF) #40%.
Patients were excluded for the presence of atrial fibrilla-
tion or flutter, second or third degree heart block, history of
life-threatening ventricular arrhythmias, recent unstable an-
gina, myocardial infarction or coronary revascularization,
uncontrolled diabetes mellitus, severe chronic obstructive
pulmonary disease, symptomatic cerebrovascular disease
within 12 months, collagen vascular disease, alcohol or drug
abuse within the prior 12 months or significant renal or
hepatic disease.
All patients gave written informed consent. Institutional
review boards for each institution approved the protocol,
which was conducted using good clinical practice.
Study design and methodology. This multicenter, ran-
domized, double-blind study consisted of three study peri-
ods. A 2- to 14-day, single-blind, placebo lead-in period
was followed by a 2-day acute, placebo-controlled, double-
blind period and a 12-week long-term, double-blind period.
During the placebo lead-in period and prior to baseline
hemodynamic measurements, dosages of required (diuret-
ics) and permitted (digoxin and nitrates) medications were
stabilized (diuretics for $2 days, digoxin for $14 days and
nitrates for $4 days). Angiotensin-converting enzyme in-
hibitor therapy was discontinued $4 days prior to baseline
hemodynamic measurements. The type and dose of ACE
inhibitor is given in Table 1. Other prohibited medications,
including vasodilators, calcium channel blockers and beta-
blockers, were discontinued $3 days prior to baseline
hemodynamic measurements. Initial hemodynamic mea-
surements, determined 2 h after placement of a Swan-Ganz
catheter, had to demonstrate that PCWP was $14 mm Hg
and cardiac index (CI) was #3.0 L/min-m2 in order for the
patient to be eligible for determination of baseline hemo-
dynamic measurements.
Baseline hemodynamic measurements were assessed
$12 h after placement of the Swan-Ganz catheter and were
required to be reproducible (i.e., PCWP, measured at
15 min intervals, differing by #10% and #2 mm Hg and CI
differing by #10%). The average of two sets of baseline
measurements of PCWP and CI had to be $14 mm Hg
and #3.0 L/min-m2, respectively, for the patient to be
eligible for randomization. Each randomized patient re-
ceived a single dose of placebo or irbesartan 12.5 mg,
37.5 mg, 75 mg, or 150 mg. Following 24 h of acute
hemodynamic assessments, patients randomized to irbesar-
tan continued to receive the same dose of irbesartan once-
daily for 12 weeks. Patients initially randomized to placebo
were reallocated to one of the four doses of irbesartan for the
12-week study period. The protocol required that the
maintenance dose of concomitant medication for the treat-
ment of heart failure remain stable, although up to three
supplemental doses of diuretic were permitted after ran-
domization. Patients who required additional medications
for the treatment of worsening heart failure were required to
be discontinued from study medication.
Hemodynamic assessments. Hemodynamic measurements
were made at baseline (prior to study medication adminis-
tration) and at 0.5, 1, 2, 3, 4, 6, 9, 12 and 24 h following the
administration of study medication. Baseline measurements
were made at least 10 h after each patient’s most recent
meal. Patients were restricted to no more than 500 ml of
oral intake following catheter insertion prior to baseline
measurements and 1600 ml oral intake during the 24-h
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BUN 5 blood urea nitrogen
CI 5 cardiac index
LVEF 5 left ventricular ejection fraction
MPAP 5 mean pulmonary arterial pressure
MRAP 5 mean right atrial pressure
MSAP 5 mean systemic arterial pressure
NYHA 5 New York Heart Association
PCWP 5 pulmonary capillary wedge pressure
Table 1. Angiotensin-Converting Enzyme Inhibitor Therapy of
Study Subjects Prior to Study Entry
Drug n
Mean Daily
Dose (mg/day)
Benazepril 9 18.9
Captopril 51 76.8
Enalapril 57 15.8
Fosinopril 8 16.9
Lisinopril 34 16.1
Quinapril 8 25.6
Ramipril 3 8.3
1175JACC Vol. 33, No. 5, 1999 Havranek et al.
April 1999:1174–81 Hemodynamic Effects of Irbesartan
measurement period. All measurements were the average of
three readings and were recorded at end expiration with the
patient in a semisupine (30°) position. For 24 h prior to
baseline hemodynamic measurements and during the 24-h
interval of hemodynamic measurements, the maintenance
doses of diuretic, digoxin and nitrate were withheld. After
12 weeks of study medication, 24-h hemodynamic readings
were repeated in the same manner as at study entry.
Neurohormonal substudy. Blood samples to assess plasma
renin activity and concentrations of aldosterone and norepi-
nephrine were collected from a subset of 48 patients at
baseline and at 2, 6, 12 and 24 h after the first and last doses
of study medication.
Safety assessments. Safety was evaluated through physical
examinations, clinical laboratory assessments and electrocar-
diograms. Spontaneously reported adverse events and ad-
verse events elicited by general questioning were recorded.
STATISTICAL ANALYSIS
The primary efficacy measure was the change from baseline
in PCWP determined at Week 12. Secondary efficacy
measures were changes from baseline in mean pulmonary
arterial pressure (MPAP); mean systemic arterial pressure
(MSAP) and heart rate at 12 weeks; acute change from
baseline in PCWP, MPAP, MSAP and heart rate after the
first dose of study medication; and change in clinical status
after 12 weeks of study medication. The protocol also
required that LVEF be assessed at baseline and again at 12
weeks after randomization either by a radionuclide tech-
nique or by two-dimensional echocardiography, using the
same technique for each determination in a given patient.
The protocol required that additional hemodynamic data,
including CI and mean right atrial pressure (MRAP) be
recorded during periods of hemodynamic monitoring.
With a sample size of 50 patients per group, there was a
90% ability to detect a 4.7 mm Hg difference in PCWP
between groups. Assuming a dropout rate of 20% (40
patients per group), the power to detect this difference in
PCWP was 81%. All tests were two-sided tests with a 5
0.05. This analysis was performed using SAS, version 6.07.
Hemodynamic effects of irbesartan were assessed by
calculating a time-weighted average change from baseline
value for each hemodynamic parameter averaged over the
first 12 h after the dose of study medication. The time-
weighted average changes in hemodynamic parameters were
compared by analysis of covariance (ANCOVA). In addi-
tion, dose-related trends in average change in hemodynamic
parameters were assessed utilizing a linear model. The effect
of irbesartan on neurohormones was assessed by calculating
the time-weighted average change from baseline value over
the first 24 h after administration of study medication.
There were fewer patients in the placebo group than in
other groups due to a delay in the entry of placebo kit
numbers into the central randomization system. This did
not affect analysis of the primary end point because placebo
patients were reallocated to active drug following the acute
hemodynamic measurements.
RESULTS
Baseline characteristics and patient disposition. Baseline
demographic, clinical and hemodynamic characteristics for
each treatment group are presented in Table 2. Baseline
demographic variables were similar among treatment
groups, although nonischemic etiologies of heart failure
were slightly more prevalent in the group randomized to
initially receive 37.5 mg of irbesartan. The disposition of
patients in the trial is presented in Figure 1. The mean
duration of the lead-in period during which patients were
not treated with ACE inhibitors was 9.1 days. No patient
Table 2. Demographic and Baseline Clinical and Hemodynamic Characteristics of Study Population at Initial
Hemodynamic Measurement*
Placebo
(n 5 30)
Irbesartan
Total
(n 5 218)
12.5 mg
(n 5 48)
37.5 mg
(n 5 47)
75 mg
(n 5 46)
150 mg
(n 5 47)
Men/Women (%) 90/10 88/12 85/15 76/24 75/26 82/18
White/Black/Other (%) 63/20/17 65/23/12 60/19/21 63/20/17 66/21/13 63/21/16
Mean age (yr) 57.6 6 10.6 61.3 6 11.3 59.8 6 11.6 60.9 6 12.4 60.4 6 12.2 60.2 6 11.7
NYHA functional class II/III/IV (%) 70/27/3 60/31/8 59/36/4 57/41/2 59/38/2 61/35/4
Ischemic etiology (%) 70 73 55 67 68 67
LVEF (%) 27.0 6 7.8 25.2 6 6.5 23.7 6 8.4 23.8 6 7.7 23.8 6 8.2 24.5 6 7.8
PCWP (mm Hg) 20.4 6 6.0 21.0 6 7.6 21.6 6 7.7 21.5 6 7.5 21.2 6 8.0 21.2 6 7.4
MPAP (mm Hg) 30.0 6 9.3 30.6 6 9.8 31.6 6 10.9 32.4 6 11.3 28.9 6 10.3 30.7 6 10.4
CI (L/min/m2) 2.28 6 0.48 2.07 6 0.41 2.09 6 0.46 2.22 6 0.42 2.09 6 0.45 2.14 6 0.44
MSAP (mm Hg) 100.1 6 12.4 97.3 6 12.6 94.7 6 13.4 97.6 6 14.2 93.4 6 9.4 96.3 6 12.6
Heart rate (beats/min) 77.7 6 15.3 79.0 6 12.0 81.4 6 15.5 76.6 6 14.5 76.8 6 13.2 78.4 6 14.0
NYHA 5 New York Heart Association; LVEF 5 left ventricular ejection fraction; PCWP 5 pulmonary capillary wedge pressure; MPAP 5 mean pulmonary arterial pressure;
CI 5 cardiac index; MSAP 5 mean systemic arterial pressure.
*Due to rounding conventions, total percent may not add up to 100. The mean 6 standard deviations are shown for selected data.
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decompensated as a result of ACE inhibitor discontinua-
tion. The adverse events requiring discontinuation of study
medication during the acute phase consisted of complete
heart block, atrial fibrillation, hypotension, nonsustained
ventricular tachycardia and a severe vasovagal reaction
during removal of the right heart catheter. During long-
term administration, adverse events requiring discontinua-
tion consisted of: worsening heart failure (n 5 10), hypo-
tension (n 5 5), laboratory abnormalities (n 5 5), acute
myocardial infarction (n 5 4), nonsustained ventricular
tachycardia (n 5 2), atrial fibrillation (n 5 1), dizziness
(n 5 1), heart transplant (n 5 1), hypertension (n 5 1),
angina pectoris (n 5 1) and respiratory infection (n 5 1).
Hemodynamic effects of irbesartan. Pulmonary capillary
wedge pressure (PCWP). The time course of change from
baseline PCWP after the first dose of study medication is
shown in Figure 2A. The largest decrease in PCWP was
seen 3 h after the administration of 150 mg of irbesartan, at
which time PCWP had decreased by 4.4 mm Hg. Decrease
from baseline PCWP was generally dose-related during the
first 12 h after administration of the first dose of study
medication. The time course of change from baseline
PCWP after administration of the Week-12 dose of study
medication is shown in Figure 3. At trough (24 h after
administration of the previous dose) PCWP had decreased
4.0 to 4.5 mm Hg in patients treated with 37.5 mg, 75 mg
or 150 mg of irbesartan and by 1.6 mm Hg in patients
treated with 12.5 mg irbesartan. Administration of a new
dose of irbesartan produced further reductions in PCWP as
shown in Table 3. Patients receiving 75 mg or 150 mg of
irbesartan had a significantly greater average decrease in
PCWP (5.3 to 5.9 mm Hg) than did patients receiving
12.5 mg of irbesartan (2.3 mm Hg), and the average
decrease in PCWP was significantly related to dose of
irbesartan (p 5 0.013). Taken together, these data indicate
that irbesartan induces significant, dose-related decreases in
PCWP that are sustained for up to 24 h after administration
of irbesartan for 12 weeks.
Mean pulmonary arterial pressure (MPAP). As shown in
Figure 2B, irbesartan induced acute, dose-related decreases
in MPAP. As shown in Table 3, the dose related-decreases
in MPAP were sustained after 12 weeks of treatment.
Mean systemic arterial pressure (MSAP). As shown in
Figure 2C, administration of irbesartan resulted in acute,
dose-related decreases in MSAP. As shown in Table 3,
long-term administration of 75 mg of irbesartan reduced
MSAP on average by 8.7 mm Hg compared with
4.0 mm Hg for 12.5 mg irbesartan, but changes in MSAP
were not clearly related to dose after 12 weeks of adminis-
tration (p 5 0.243).
Heart rate. As shown in Figure 2D and in Table 3, there
were no significant dose-related effects of irbesartan on
heart rate during either acute or long-term administration.
Cardiac index (CI). There were no significant acute
changes in CI seen with the administration of the first dose
of study medication. After administration of 12 weeks of
irbesartan, there was a small increase in average CI in the
37.5 mg dose group (0.3 L/min-m2) compared with the
12.5 mg group (0.1 L/min-m2, p , 0.05), but increases in
CI were not generally dose-related at Week 12 (p 5 0.56)
(Table 3).
Left ventricular ejection fraction (LVEF). There was a
tendency for LVEF to increase as a function of dose of
irbesartan (p 5 0.088). Irbesartan 75 mg and 150 mg
produced greater average changes in LVEF when compared
with irbesartan 12.5 mg; however, these changes did not
achieve statistical significance (Table 3).
Clinical effects of irbesartan. The number of patients
discontinuing study medication and the number of patients
hospitalized for heart failure are shown in Table 4. Discon-
tinuation of study medication as a consequence of worsen-
ing heart failure decreased as a function of dose of irbesartan
(p 5 0.045). Death, discontinuation of study medication for
worsening heart failure or hospitalization for worsening
heart failure occurred in 13.9% of patients receiving either
12.5 mg or 37.5 mg of irbesartan as compared with 5.5% of
patients receiving either 75 mg or 150 mg of irbesartan (p 5
0.04). Discontinuation of study medication and hospitaliza-
tion for worsening heart failure were at the discretion of the
individual investigator.
Neurohormonal effects of irbesartan. As shown in Table
5, plasma renin activity tended to increase as a function of
dose of irbesartan while serum aldosterone and plasma
Figure 1. Patient disposition. Reasons for discontinuation of study
medication are shown.
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norepinephrine tended to decrease in the 150 mg group
after the first dose of study medication. In general, the
variability of the data was too large to detect statistically
significant changes in neurohormone levels following 12
weeks of therapy, perhaps in part because of variability in
baseline disease severity.
Safety and tolerability of irbesartan. Three deaths (two
deaths in the 37.5 mg group, one death in the 150 mg
group) occurred during the 12-week treatment period. Each
death was either sudden or unwitnessed.
One patient in the placebo group, two patients in the
75 mg group and two patients in the 150 mg group
discontinued study medication due to adverse events during
the acute phase of the study. During the long-term phase of
the study, adverse events lead to the discontinuation of study
medication in 6 (11%) patients in the 12.5 mg group, 14
(26%) patients in the 37.5 mg group, 4 (8%) patients in the
75 mg group and 8 (15%) patients in the 150 mg group.
Hypotension was reported as an adverse event in three
patients (1.6%) during the acute phase of the study (one
patient receiving 37.5 mg irbesartan and two patients
receiving 150 mg irbesartan). During the long-term phase
of the study, hypotension or orthostatic hypotension was
reported as an adverse event in an additional 12 (5.7%)
patients, including 1 patient (1.9%) receiving 12.5 mg
irbesartan, 4 patients (7.4%) receiving 37.5 mg irbesartan, 1
patient (1.9%) receiving 75 mg irbesartan and 6 patients
(11.3%) receiving 150 mg irbesartan. There was no evidence
for dose-related increases in the frequency of adverse events
related to either cough or azotemia. There were no statis-
tically significant changes in blood urea nitrogen (BUN),
creatinine, potassium or uric acid at Week 12 compared
with baseline.
DISCUSSION
Hemodynamic effects of irbesartan. Patients who have
marked elevation of resting PCWP in the setting of heart
failure are at increased risk for adverse clinical outcome
(15,16). Irbesartan induced significant, dose-related reduc-
tions in PCWP that were sustained after 12 weeks of
treatment. The magnitude of this effect, 5–6 mm Hg with
75-mg or 150-mg doses, is clinically important. Irbesartan
Figure 2. Acute hemodynamic effects of irbesartan. The time course of change from baseline value after the first dose of study medication
is shown for pulmonary capillary wedge pressure (PCWP, Fig. 2A), mean pulmonary artery pressure (MPAP, Fig. 2B), mean systemic
arterial pressure (MSAP, Fig. 2C) and heart rate (HR, Fig. 2D).
Figure 3. Long-term effects of irbesartan on pulmonary capillary
wedge pressure (PWCP). The time course of change from baseline
value for PCWP is shown immediately before (Time 0) and for
24 h after the administration of the last dose of study medication
at Week 12.
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produced reductions in PCWP 24 h after dosing, indicating
that once-per-day dosing with irbesartan provides sustained
reductions in left ventricular filling pressure during long-
term treatment. Irbesartan also induced dose-related, sus-
tained reductions in MPAP. The decrease in blood pressure
was not dose-related as shown by the range of doses
characterized in the study, in contrast to the dose-related
reduction in systemic arterial pressure that is seen in
mild-to-moderate hypertension (17,18). Attenuation of
blood pressure lowering at higher doses of AT1 receptor
antagonists has been reported previously in patients with
heart failure (2). Although irbesartan lowered left ventric-
ular filling pressures, CI was maintained during long-term
treatment. These hemodynamic effects of irbesartan were
not accompanied by reflex tachycardia.
Clinical effects of irbesartan. Discontinuation of study
medication due to worsening heart failure was significantly
reduced in a dose-related manner by irbesartan. Since the
protocol required discontinuation of study medication in
patients who needed new medications or an increase in the
maintenance dose of concomitant medications for heart
failure, these data indicate that irbesartan prevented wors-
ening of heart failure in a dose-related manner and provide
a clinical correlate to the dose-related improvement in
PCWP.
Neurohormonal effects of irbesartan. There was a ten-
dency for irbesartan to induce an acute increase in plasma
renin activity. This is likely to be due to blockade of AT1
receptors located in the juxtaglomerular apparatus of the
kidney and has been reported previously during the acute
administration of AT1 receptor antagonists in patients with
heart failure (2,3). In the 150 mg irbesartan group, serum
aldosterone and plasma norepinephrine levels tended to
decrease acutely and during long-term administration.
Safety and tolerability of irbesartan. Irbesartan was gen-
erally well-tolerated in this 12-week study of patients with
mild-to-severe heart failure. Discontinuation of study med-
ication and adverse events were not related to dose of
irbesartan.
Comparison with previous studies. The results of this
study are consistent with and confirm the results of a
previous study in which 96 patients with heart failure
received either placebo or single doses of irbesartan ranging
from 1 mg to 200 mg. In the previous study, irbesartan
acutely decreased PCWP, mean systemic arterial pressure
and heart rate while maintaining CI (19).
Previous studies with the AT1 receptor antagonist losar-
tan demonstrated reductions in PCWP, MSAP, systemic
vascular resistance and heart rate associated with an increase
in CI in patients with heart failure (2,3). There is a
preliminary report that administration of the AT1 receptor
antagonist valsartan, at a dose of 160 mg twice daily to
patients already being treated with ACE inhibitors, results
in acute and long-term reduction of PCWP (20). Irbesartan
was well tolerated in two additional studies of patients with
heart failure (21,22).
Whether AT1 receptor antagonism provides survival that
is comparable with or superior to inhibition of ACE needs
to be addressed in a prospectively designed mortality trial of
sufficient size and duration.
Study limitations. Ethical considerations preclude assess-
ment of the effects of irbesartan or other AT1 receptor
antagonists in a long-term, placebo-controlled trial in pa-
tients not receiving ACE inhibitors.
Thus, the long-term phase of this study was not placebo-
controlled. The 12.5 mg irbesartan group served as a control
during the long-term phase of the study, and the analysis of
data was based upon comparison of the 12.5 mg group with
groups receiving higher doses and by assessment of dose-
related trends in the data. This design is likely to provide a
conservative estimate of what the treatment effect would
have been in a placebo-controlled trial. Given the small
number of NYHA class IV patients included in the trial, the
Table 3. Average Changes from Baseline in Hemodynamic Variables at Week 12
PCWP*
mm Hg
MPAP†
mm Hg
MSAP
mm Hg
HR
beats/min
CI
L/minzm2
LVEF‡
units
Irbesartan 12.5 mg 22.3 6 0.9 0.2 6 1.1 24.0 6 1.2 0.3 6 1.4 0.1 6 0.1 1.7 6 1.0
Irbesartan 37.5 mg 24.8 6 1.0 24.2 6 1.1 25.9 6 1.3 3.2 6 1.5 0.3 6 0.1 0.8 6 1.1
Irbesartan 75 mg 25.9 6 0.9 25.4 6 1.1 28.7 6 1.2 23.3 6 1.4 0.1 6 0.1 2.2 6 1.0
Irbesartan 150 mg 25.3 6 0.9 23.0 6 1.1 25.3 6 1.2 20.6 6 1.4 0.2 6 0.1 3.8 6 1.0
*p 5 0.013 for dose-related trend; †p 5 0.021 for dose-related trend; ‡p 5 0.088 for dose-related trend.
PCWP 5 pulmonary capillary wedge pressure; MPAP 5 mean pulmonary arterial pressure; MSAP 5 mean systemic arterial pressure; HR 5 heart rate; CI 5 cardiac index;
LVEF 5 left ventricular ejection fraction.
Table 4. Drug Discontinuation or Hospitalization for
Worsening Heart Failure
Irbesartan
12.5 mg 37.5 mg 75 mg 150 mg
Discontinued due
to worsening
heart failure
5 6 2 1
Hospitalized due
to worsening
heart failure
3 3 2 2
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results are most applicable to patients with mild-to-
moderate heart failure.
Conclusions. In conclusion, the once-daily administration
of irbesartan 75 mg or 150 mg to patients with symptomatic
heart failure (NYHA functional class II, III or IV) and
LVEF ,240% was well-tolerated, resulted in sustained
hemodynamic improvement and prevented worsening heart
failure. Irbesartan appears to be a promising new therapy for
patients with chronic heart failure.
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